Dr. Cobleigh on the Focus of Future Research in HER2+ Breast Cancer

11 Jun, 2019 ,

Dr. Cobleigh discusses the focus of future research in HER2-positive breast cancer. One of the goals of future research should be to eliminate the need for chemotherapy, says Cobleigh. That may become a reality with antibody-drug conjugates (ADCs), which are essentially a less toxic form of traditional cytotoxics. Additionally, some of the bispecific antibodies that are trying to bring the immune system to the HER2 receptor is a very promising area of research.